Two West Coast companies – Pascal Biosciences and SoRSE Technology – are collaborating to move the cannabinoid PAS-393 into clinical trials to test the drug’s effectiveness on a common immune-evading strategy that many metastatic cancers em…
Two West Coast companies – Pascal Biosciences and SoRSE Technology – are collaborating to move the cannabinoid PAS-393 into clinical trials to test the drug’s effectiveness on a common immune-evading strategy that many metastatic cancers em…